Further studies to evaluate the functions of CPXM1 and other genes that undergo aberrant DNA methylation will advance our understanding of the role of aberrant DNA methylation in arsenic bladder carcinogenesis and will also facilitate the identification of novel therapeutic targets for arsenic-related bladder cancers. This evidence concerns the gene CPXM1 and urinary bladder carcinoma.